GH Research (GHRS) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.18

Estimate

-$0.30

Surprise

+40.4%

Score today

5.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

GH Research (GHRS) reported a narrower loss than forecast — adjusted EPS of -$0.18 against the -$0.30 estimate (a 40.4% beat on a still-unprofitable quarter).

• RBC Capital Maintains Buy Rating on GH Research — fiscal.ai, 2026-11-15
• GH Research Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-13
• GH Research Appoints Dr. Vanina Popova as Chief Development Officer — fiscal.ai, 2026-11-13

TrendMatrix currently rates GHRS Sell at 5.9/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +40.4% surprise compares with a +16.6% four-quarter average. Next scheduled report: 2027-03-04.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$19.10

Price target

$37.31

Stop

$17.76

Upside to target

+95.3%

Reward-to-risk

6.8:1

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.31B

P/E (fwd)

-10.6

52-week range

$12.04–$31.44

Off 52-week high

39.2%

RSI (14)

50

Volume vs avg

1.64×

Score today

5.9/10